NO20020213L - Svovelsyre mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin- 4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester - Google Patents

Svovelsyre mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin- 4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester

Info

Publication number
NO20020213L
NO20020213L NO20020213A NO20020213A NO20020213L NO 20020213 L NO20020213 L NO 20020213L NO 20020213 A NO20020213 A NO 20020213A NO 20020213 A NO20020213 A NO 20020213A NO 20020213 L NO20020213 L NO 20020213L
Authority
NO
Norway
Prior art keywords
phenyl
piperidin
fluoro
methoxy
hydroxy
Prior art date
Application number
NO20020213A
Other languages
English (en)
Other versions
NO20020213D0 (no
NO324177B1 (no
Inventor
Ronald Bernotas
Paul Brown
Gary Emmons
Chi-Hsin R King
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20020213D0 publication Critical patent/NO20020213D0/no
Publication of NO20020213L publication Critical patent/NO20020213L/no
Publication of NO324177B1 publication Critical patent/NO324177B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20020213A 1999-07-16 2002-01-15 Svovelsyremono-[3-({1-[2-(4-fluor-fenyl)-etyl]-piperidin-4-YL}-hydroxy-metyl)-2-metoksy-fenyl]ester, fremgangsmate for fremstilling derav samt mellomprodukt, fremgangsmate for a isolere forbindelsen, anvendelse av forbindelsen samt farmasoytisk sammensetning NO324177B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35470499A 1999-07-16 1999-07-16
PCT/US2000/019065 WO2001005764A2 (en) 1999-07-16 2000-07-13 Sulfuric acid mono-[3-({1- [2-(4-fluoro-phenyl)-ethyl]- piperidin-4-yl}- hydroxy- methyl)-2- methoxy-phenyl]ester

Publications (3)

Publication Number Publication Date
NO20020213D0 NO20020213D0 (no) 2002-01-15
NO20020213L true NO20020213L (no) 2002-02-22
NO324177B1 NO324177B1 (no) 2007-09-03

Family

ID=23394565

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020213A NO324177B1 (no) 1999-07-16 2002-01-15 Svovelsyremono-[3-({1-[2-(4-fluor-fenyl)-etyl]-piperidin-4-YL}-hydroxy-metyl)-2-metoksy-fenyl]ester, fremgangsmate for fremstilling derav samt mellomprodukt, fremgangsmate for a isolere forbindelsen, anvendelse av forbindelsen samt farmasoytisk sammensetning

Country Status (21)

Country Link
EP (1) EP1202967B1 (no)
JP (1) JP2003505374A (no)
KR (1) KR100737718B1 (no)
AR (1) AR024762A1 (no)
AT (1) ATE348807T1 (no)
AU (1) AU769484B2 (no)
BR (1) BR0012477A (no)
CA (1) CA2374635C (no)
CY (1) CY1107658T1 (no)
DE (1) DE60032489T2 (no)
DK (1) DK1202967T3 (no)
ES (1) ES2276688T3 (no)
HU (1) HUP0202297A3 (no)
IL (2) IL147310A0 (no)
MX (1) MXPA02000444A (no)
NO (1) NO324177B1 (no)
NZ (1) NZ516286A (no)
PL (1) PL353749A1 (no)
PT (1) PT1202967E (no)
WO (1) WO2001005764A2 (no)
ZA (1) ZA200200101B (no)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
KR100211713B1 (ko) * 1990-06-01 1999-08-02 슈테펜 엘. 네스비트 (+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists

Also Published As

Publication number Publication date
CY1107658T1 (el) 2013-04-18
EP1202967B1 (en) 2006-12-20
EP1202967A2 (en) 2002-05-08
HUP0202297A2 (en) 2002-10-28
PT1202967E (pt) 2007-02-28
MXPA02000444A (es) 2002-07-02
ZA200200101B (en) 2003-06-25
WO2001005764A2 (en) 2001-01-25
AU6093900A (en) 2001-02-05
NO20020213D0 (no) 2002-01-15
NZ516286A (en) 2004-03-26
DK1202967T3 (da) 2007-04-10
CA2374635C (en) 2007-04-17
KR100737718B1 (ko) 2007-07-11
WO2001005764A3 (en) 2001-10-04
DE60032489D1 (de) 2007-02-01
CA2374635A1 (en) 2001-01-25
IL147310A (en) 2007-10-31
HUP0202297A3 (en) 2010-01-28
AR024762A1 (es) 2002-10-23
NO324177B1 (no) 2007-09-03
AU769484B2 (en) 2004-01-29
PL353749A1 (en) 2003-12-01
JP2003505374A (ja) 2003-02-12
BR0012477A (pt) 2002-04-02
ATE348807T1 (de) 2007-01-15
IL147310A0 (en) 2002-08-14
KR20020042619A (ko) 2002-06-05
ES2276688T3 (es) 2007-07-01
DE60032489T2 (de) 2007-10-11

Similar Documents

Publication Publication Date Title
DE60024345D1 (de) Polymerelektrolyt
ID22095A (id) Asam aril-akrilat ester
NO20006114L (no) Nytt 3-aryl-2-hydroksypropionsyrederivat III
EE200100708A (et) Asendatud fenoksüäädikhapped
DE60009108D1 (de) Batteriedose
ATE316093T1 (de) Glucopyranosid-konjugate von 2-(4-hydroxy-phenyl)-1-(4-(2-amin-1-yl-ethoxy)- enzyl)-1h-indol-5-olen
EP1158588A4 (en) ELECTROCHEMICAL CONDENSER
NO20020213L (no) Svovelsyre mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin- 4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
ID26146A (id) Proses untuk cis-1-{2-[4-(6-metoksi-2-fenil-1,2,3,4-tetrahidronaftalen-1-il]fenoksi]etil} pirolidin
LT2000075A (lt) Nauja 6-hidroksi-3(4-[2-(piperidin-1-il)-etoksi]fenoksi)-2-(4-metoksifenil)benzo[b]tiofeno hidrochlorido kristalinė forma
ATE315025T1 (de) Ethansulfonyl-piperidin-derivate
LT2000076A (lt) Nauja 6-hidroksi-3(4-[2-(piperidin-1-il)-etoksi]fenoksi)-2-(4-metoksifenil)benzo[b]tiofeno hidrochlorido kristalinė forma
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
ID24964A (id) Bentuk-bentuk baru psendopolimorf dari asam dihidroklorida 2-[2-[4-[bis (4-fluorofenil) metil]-1-piperazinil) etoksi asetat
SI1202967T1 (sl) Mono-(3-(1-(2-(4-fluoro-fenil)-etil)-piperidin-4-il)-hidroksi-metil)-2- metoksi-fenil)ester zveplove kisline
FI19992215A7 (fi) Kalanterointimenetelmä
DK1202966T3 (da) Piperidinalkoholer
FI991093A7 (fi) Yhteyksien hallintamenetelmä
FR2797350B1 (fr) Plaque d'electrode pour accumulateur
FI19992633L (fi) Paperin lujuuteen vaikuttavat koostumukset
FI19992027L (fi) Menetelmä seinäelementtien ja sokkelin rakentamiseksi
FR2795387B1 (fr) Caisse americaine hermetique
UA34022A (uk) Спосіб підвищення висоти прикусу
SE9801991D0 (sv) New 3-aryl-2-hydroxypropionic acid derivative II
SE9900999D0 (sv) Skarvlist/anslutningslist

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees